Akebia Therapeutics (AKBA) 10-Q 2019 Q3 Quarterly report

Exhibit 32.1

CERTIFICATION PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 (18 U.S.C. Section 1350)

In connection with the accompanying Quarterly Report of Akebia Therapeutics, Inc. (the “Company”) on Form 10-Q for the fiscal quarter ended September 30, 2019 (the “Report”), I, John P. Butler, as Chief Executive Officer and President of the Company, and I, Jason A. Amello, as Senior Vice President, Chief Financial Officer and Treasurer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to my knowledge:

1. The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: November 12, 2019	By:	/s/ John P. Butler
		John P. Butler
		President, Chief Executive Officer and Director
		(Principal Executive Officer)
Date: November 12, 2019	By:	/s/ Jason A. Amello
		Jason A. Amello
		Senior Vice President, Chief Financial Officer and Treasurer
		(Principal Financial Officer)